2. Cell Cycle/DNA Damage
    Cytoskeleton
  3. Kinesin

Kinesin

Kinesin

Related Products

PDF 0.04 MB

Kinesins are a family of molecular motors that use the energy of ATP hydrolysis to move along the surface of, or destabilize, microtubule filaments. The kinesin motor protein family consists of 14 distinct subclasses and 45 kinesin proteins in humans. A large number of these proteins, or their orthologues, have been shown to possess essential function(s) in both the mitotic and the meiotic cell cycle. Kinesins also can be classified into three groups based on the position of their motor domains: N-terminal, C-terminal and internal kinesins. Conventional kinesin operates as a dimer, walking in a co-ordinated, hand-over-hand fashion along a microtubule protofilament.

Kinesins have important roles in chromosome separation, microtubule dynamics, spindle formation, cytokinesis and cell cycle progression. Roles of kinesins in diseases typically involve defective transport of cell components, transport of pathogens, or cell division.

Kinesin Related Products (83):

Cat. No. Product Name Effect Purity
  • HY-10299
    GSK-923295 Inhibitor 99.82%
    GSK-923295 is a special, allosteric inhibitor of centromere-associated protein-E (CENP-E) kinesin motor ATPase activity, with Ki of 3.2±0.2 nM and 1.6± 0.1 nM for human and canine, respectively.
  • HY-50759
    Ispinesib Inhibitor 99.62%
    Ispinesib is a specific inhibitor of kinesin spindle protein (KSP), with a Ki app of 1.7 nM.
  • HY-132840
    Sovilnesib Inhibitor
    Sovilnesib (AMG 650) is a potent, orally active kinesin-like protein KIF18A inhibitor with an IC50 value of 0.071 μM. Sovilnesib can be used for the research of cancer[1][2].
  • HY-101071A
    Monastrol Inhibitor 99.89%
    Monastrol is a potent and cell-permeable inhibitor of the mitotic kinesin Eg5 with an IC50 value of 14 μM.
  • HY-15187
    Filanesib Inhibitor
    Filanesib (ARRY-520) is a selective and noncompetitive kinesin spindle protein (KSP) inhibitor, with an IC50 of 6 nM for human KSP. Filanesib induces cell death by apoptosis in vitro. Filanesib has potent anti-proliferative activity[1].
  • HY-110090
    UA62784 Inhibitor
    UA62784 is a microtubule polymerization inhibitor that interacts with tubulin dimers. UA62784 is a novel specific inhibitor of centromere protein E (CENP-E) kinesin. UA62784 can be used for the study of pancreatic cancer[1][2].
  • HY-170850
    MKLP2-IN-1 Inhibitor
    MKLP2-IN-1 (compound 12a) is an inhibitor of MKLP2 with good oral bioavailability. MKLP2-IN-1 inhibits the microtubule-stimulated ATPase activity of recombinant MKLP2 in vitro and suppresses tumor growth in a mouse Calu-6 lung cancer model[1].
  • HY-164979
    KIF18A-IN-15 Inhibitor
    KIF18A-IN-15 (Compound Example 36) is a KIF18A inhibitor, available in two forms, EX36-A and its enantiomer EX36-B, with IC50s of 0.01-0.1 μM, respectively. EX36-A and EX36-B inhibit OVCAR-3 cells viability with IC50s of 0.01-0.1 μM and 0-0.01 μM, respectively. KIF18A-IN-15 can be used in tumor (e.g. colon, breast, lung) studies[1].
  • HY-115570A
    (Z/E)-GW406108X Inhibitor
    (Z/E)-GW406108X is a mixture of different configurations of GW406108X (HY-115570). GW406108X is a specific Kif15 (Kinesin-12) inhibitor with an IC50 of 0.82 uM[1].
  • HY-50672
    MK-0731 Inhibitor 99.85%
    MK-0731 is a selective, non-competitive and allosteric kinesin spindle protein (KSP) inhibitor with an IC50 of 2.2 nM and a pKa of 7.6. MK-0731 is >20,000 fold selectivity against other kinesins. MK-0731 induces mitotic arrest and induces apoptosis in tumors. MK-0731 provides significant antitumor efficacy[1][2].
  • HY-101071
    (S)-Monastrol Inhibitor
    (S)-Monastrol ((+)-Monastrol) is an allosteric inhibitor of the mitotic kinesin Eg5 that exhibits an antiproliferative effect against several cancer cell lines. (S)-Monastrol arrests mammalian cells in mitosis with monopolar spindles[1][2].
  • HY-146146
    Kolavenic acid analog Inhibitor
    Kolavenic acid analog (KAA) is an anticancer agent. Kolavenic acid analog shows strong activity against HSET-overproducing yeast cells. Kolavenic acid analog inhibits centrosome clustering in human cancer cells containing high HSET levels and supernumerary centrosomes[1].
  • HY-RS07262
    Kif14 Mouse Pre-designed siRNA Set A Inhibitor

    Kif14 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Kif14 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

  • HY-117440
    4'-Methoxy-S-trityl-L-cysteinol Inhibitor
    4'-Methoxy-S-trityl-L-cysteinol is an allosteric inhibitor of vertebrate Kinesin Spindle Protein (KSP). 4'-Methoxy-S-trityl-L-cysteinol significantly enhances its inhibitory activity against NCI60 tumor cells by modifying the trityl and cysteine groups. Its EC50 for bipolar spindle formation is 28 μM, showing stronger inhibitory potency than the parent molecule and monastrol.
  • HY-N11128
    Solidagonic acid Inhibitor
    Solidagonic acid inhibits HSET motor activity by promoting the conversion from abnormal monopolar to bipolar spindles. Solidagonic acid suppresses fission yeast cell death and enables reversion of the mitotic spindles from a monopolar to bipolar morphology. Solidagonic acid showed the growth inhibitory activity on the seedlings of Lactuca sativa L. and Lolium multiflorum Lam[1][2].
  • HY-14846
    Litronesib Inhibitor 99.59%
    Litronesib (LY2523355) is a selective mitosis-specific kinesin Eg5 inhibitor, with antitumor activity[1].
  • HY-155134
    Eg5-IN-1 Inhibitor
    Eg5-IN-1 (compound 6c) is a potent kinesin family motor protein (Eg5) inhibitor with an IC50 value of 1.97 µM. Eg5-IN-1 can be used in research of cancer[1].
  • HY-RS07263
    Kif14 Rat Pre-designed siRNA Set A Inhibitor

    Kif14 Rat Pre-designed siRNA Set A contains three designed siRNAs for Kif14 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

  • HY-162937
    KIF18A-IN-13 Inhibitor
    KIF18A-IN-13 (Compound 16) is an effective and orally active inhibitor of KIF18A with anticancer activity in vivo. KIF18A-IN-13 can be utilized for research in ovarian cancer[1].
  • HY-145827
    KIF18A-IN-4 Inhibitor
    KIF18A-IN-4 is a moderately potent ATP and microtubule (MT) noncompetitive KIF18A inhibitor (IC50=6.16 μM). KIF18A-IN-4 has selectivity against a large panel of mitotic kinesins and kinases, and does not show any direct effects on tubulin assembly. KIF18A-IN-4 exhibits anti-tumor activity[1].